New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival AdvantageSALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene ...
Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment ...
78% of participants across both groups received standard ALS background therapy (riluzole, edaravone, or both) at baseline. These results are consistent with previous survival benefits observed in ...
The third ALS treatment to be given FDA approval, following Mitsubishi Tanabe’s Radicava ($170,000 per year) and generic drug riluzole – Relyvrio is priced at around $12,500 per 28-day ...
Despite the best efforts of drug developers, just a handful of disease-modifying drugs, such as Mitsubishi Tanabe's Radicava (edaravone) and generic drug riluzole, have been approved for ALS ...
Lip twitching happens when your upper or bottom lip shakes, trembles, or quivers uncontrollably. It may be caused by something as simple as drinking too much caffeine or being low in potassium, but, ...
CNM-Au8 prolonged survival for people with ALS relative to those who received the investigational treatment zilucoplan or a ...
It was October 2024, and my husband Andrew had just been diagnosed with motor neurone disease (MND) aged 51 – which affects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback